糖尿病藥物市場規模、佔有率、成長分析（按糖尿病類型、藥物類型、最終用戶和地區分類）- 2025 年至 2032 年產業預測

全球糖尿病藥物市場預計將在 2023 年達到 712 億美元，從 2024 年的 761.1 億美元成長到 2032 年的 1,298 億美元，預測期內（2025-2032 年）的複合年成長率為 6.9%。

由於糖尿病盛行率不斷上升、創新療法不斷進步以及醫療保健格局的不斷演變，全球糖尿病藥物市場正經歷強勁成長。全球人口老化正在創造巨大的市場機會，因為老年人更容易罹患糖尿病。此外，都市化和生活方式的改變導致糖尿病風險增加，進一步推動了市場擴張。認知度的提高和早期發現正在推動糖尿病治療。個人化和精準醫療的趨勢正在推動客製化治療方案的製定，以提高療效。人工智慧、機器學習、物聯網和區塊鏈等技術的整合正在徹底改變藥物研發和疾病管理。這些技術創新提供即時監控和洞察，從而提高治療依從性，改善糖尿病護理中患者的整體預後。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與約束

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 技術評估
• 監管格局
• 客戶和購買標準分析
• 管道分析
• 疾病流行病學

糖尿病治療藥物市場規模（依糖尿病類型及複合年成長率）（2025-2032）

• 市場概況
• 1型糖尿病
• 2型糖尿病
• 妊娠糖尿病

糖尿病治療藥物市場規模（按藥物類型和複合年成長率）（2025-2032）

• 市場概況
• 口服抗糖尿病藥物
• 注射型抗糖尿病藥物

糖尿病治療藥物市場規模（按最終用戶和複合年成長率分類）（2025-2032）

• 市場概況
• 醫院
• 診所
• 個人使用

糖尿病治療藥物市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 按部門分類的公司佔有率分析
  • 收益同比比較（2022-2024 年）

主要企業簡介

• Novo Nordisk（Denmark）
• Eli Lilly and Company（USA）
• Sanofi（France）
• Merck & Co.（USA）
• AstraZeneca（UK）
• Boehringer Ingelheim（Germany）
• Takeda Pharmaceutical Company（Japan）
• Johnson & Johnson（USA）
• Novartis（Switzerland）
• Bristol Myers Squibb（USA）
• Pfizer（USA）
• Roche（Switzerland）
• Bayer AG（Germany）
• AbbVie（USA）
• Daiichi Sankyo（Japan）
• Gilead Sciences（USA）
• AstraZeneca（UK）
• Amgen（USA）
• GlaxoSmithKline（UK）
• Biocon（India）

結論和建議

Global Diabetes Therapeutics Market size was valued at USD 71.2 billion in 2023 and is poised to grow from USD 76.11 billion in 2024 to USD 129.8 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The global diabetes therapeutics market is experiencing robust growth due to increasing prevalence of diabetes, innovative treatment advancements, and evolving healthcare dynamics. A rising aging population worldwide creates significant market opportunities, as older individuals are more susceptible to diabetes. Additionally, urbanization and lifestyle changes are contributing to heightened diabetes risks, further driving market expansion. Enhanced awareness and early detection are motivating individuals to seek diabetes therapies. The trend towards personalized and precision medicine is fostering tailored treatment solutions that enhance effectiveness. Technological integration, including AI, machine learning, IoT, and blockchain, is revolutionizing drug discovery and disease management. These innovations provide real-time monitoring and insights, thereby promoting better treatment adherence and improving overall patient outcomes in diabetes care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetes Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Diabetes Therapeutics Market Segments Analysis

Global Diabetes Therapeutics Market is segmented by Diabetes Type, Drug Type, End User and region. Based on Diabetes Type, the market is segmented into Type 1 Diabetes, Type 2 Diabetes and Gestational Diabetes. Based on Drug Type, the market is segmented into Oral Antidiabetics and Injectable Antidiabetics. Based on End User, the market is segmented into Hospitals, Clinics and Personal Use. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Diabetes Therapeutics Market

The global demand for diabetes therapeutics is being significantly driven by the rising prevalence of both type 1 and type 2 diabetes. This demand is further amplified by an aging population, as older individuals are more susceptible to developing diabetes. Additionally, the escalating rates of obesity, coupled with sedentary lifestyles and unhealthy dietary choices, contribute to market growth by leading to higher levels of insulin resistance and various metabolic disorders. These factors collectively underscore the urgent need for effective diabetes management solutions, propelling the expansion of the diabetes therapeutics market on a worldwide scale.

Restraints in the Global Diabetes Therapeutics Market

The Global Diabetes Therapeutics market faces notable challenges due to the substantial expenses associated with the ongoing management of both type 1 and type 2 diabetes. Effective treatment often necessitates a lifelong commitment to purchasing insulin, medications, therapies, and glucose monitoring equipment, which can pose a significant financial burden. Individuals lacking adequate health insurance or access to quality healthcare services often struggle to afford necessary diabetes therapeutics, particularly in the absence of reimbursement options. Furthermore, the escalating costs associated with novel biologics and personalized medicine are creating barriers to innovation within the diabetes therapeutics sector, hindering advancements and limiting access for patients.

Market Trends of the Global Diabetes Therapeutics Market

The Global Diabetes Therapeutics market is witnessing a significant trend towards the adoption of personalized and precision medicine, focusing on individualized treatment approaches that cater to distinct genetic profiles, metabolic variations, and lifestyle factors. This shift aims to address the root causes of diabetes by improving insulin sensitivity and overall therapeutic efficacy. With advancements in biotechnology and a growing emphasis on tailored healthcare solutions, these innovative therapies are becoming increasingly accessible and cost-effective, fostering greater acceptance and adherence among patients. As a result, this trend is poised to reshape the landscape of diabetes management by enhancing treatment outcomes and patient experiences.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Diabetes Therapeutics Market Size by Diabetes Type & CAGR (2025-2032)

• Market Overview
• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

Global Diabetes Therapeutics Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Oral Antidiabetics
• Injectable Antidiabetics

Global Diabetes Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Personal Use

Global Diabetes Therapeutics Market Size & CAGR (2025-2032)

• North America (Diabetes Type, Drug Type, End User)
  • US
  • Canada
• Europe (Diabetes Type, Drug Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diabetes Type, Drug Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diabetes Type, Drug Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diabetes Type, Drug Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations